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ABSTRACT: Objective: We investigated the trend of asymmetric dimethylarginine (ADMA) and
symmetric dimethylarginine (SDMA) in patients with severe sepsis and septic shock, and the rela-
tionship between dimethylarginines, organ failure, sepsis status and intensive care unit (ICU) mor-
tality.
Design: A prospective observational study carried out in three general adult Italian ICUs.
Patients: Consecutive patients with severe sepsis or septic shock admitted to ICUs between Decem-
ber 2004 and March 2007.
Methods: Plasma ADMA and SDMA were determined immediately after enrolment and on the
third, sixth and twelfth days. Organ failure score, sepsis status, standard blood parameters and
ICU outcome were collected.
Results: Twenty-nine consecutive patients were enrolled. ADMA and SDMA were higher in pa-
tients than in healthy volunteers. Sixteen patients who suffered from septic shock during ICU stay
had a higher average value of daily ADMA and SDMA. ADMA was significantly related to arterial
pH. SDMA was related to diabetes mellitus, Simplified Acute Physiology Score II, arterial pH level,
daily Sequential Organ Failure Assessment score, and creatinine. Independent variables predicting
ICU mortality were Simplified Acute Physiology Score II, mean Sequential Organ Failure Assess-
ment score, and SDMA.
Conclusion: Dimethylarginines are not only markers of body catabolism but may have a high
metabolic activity, tightly related to the risk of adverse outcome of sepsis syndrome. (Nutritional
Therapy & Metabolism 2007; 25: 189-94)
KEY WORDS: Sepsis, Dimethylarginines, Nitric oxide, Organ failure, Intensive care unit, Critical-
ly ill
INTRODUCTION
The biosynthesis of symmetric dimethylarginine
(SDMA) and asymmetric dimethylarginine (ADMA) oc-
curs during the methylation of protein arginine residues
in a process catalyzed by the action of protein arginine
methyltransferases I and II (1). Type I protein arginine
methyltransferase is responsible for the formation of
ADMA, while type II protein arginine methyltransferase
produces SDMA. Protein methylation is principally irre-
versible and arginine-methylated proteins are mainly en-
gaged in RNA processing, transcriptional control and nu-
cleocytoplasmic transport (2, 3). Methylated proteins re-
lease ADMA and SDMA upon their proteolytic degrada-
tion during physiological protein turnover. 
A major metabolic route for ADMA is decomposi-
tion to citrulline and dimethylamine in a reaction cat-
alyzed by dimethylarginine dimethylaminohydrolase,
highly expressed under normal conditions in liver, kid-
ney, pancreas and endothelial cells. It is besides eliminat-
ed by renal excretion (4, 5). SDMA seems to be strictly
eliminated by renal excretion (6, 7). Dimethylarginines
compete with arginine for cationic amino acid trans-
porters of system y+ (8), whereas ADMA is also an en-
dogenous inhibitor of all isoforms of nitric oxide syn-
thase (NOS) (9, 10).
The free radical nitric oxide (NO), produced from L-
arginine by constitutive and inducible isoforms of syn-
thase, is recognized as a potent multifunctional molecule
which may play a both beneficial and detrimental role in
vivo. Constitutive NO acts as a neurotransmitter and reg-
ulates vascular tone as well as deregulating the interac-
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tion between vascular endothelium and blood platelets
and leukocytes (11). NO synthesized by inducible NOS
has an immunoregulatory function: it modulates cytokine
production and cytoprotection as a free radical scavenger
(12). Increased NO production by inducible NOS and de-
creased production by constitutive NOS seem to occur in
infection, inflammation, trauma, heart attack, renal fail-
ure, sepsis resulting in oxidative stress, excessive inflam-
mation, disseminated coagulopathy, alteration of mi-
crovascular endothelium, organ perfusion and resulting
organ injury. However, administration of NG-
monomethylarginine, a pharmacological nonspecific
NOS inhibitor analogous to ADMA, led to increased
mortality in septic patients (13), documenting an adverse
effect on nonselective NO inhibition. 
Critically ill patients are hypercatabolic and may pre-
sent impaired renal and hepatic function. In addition, di-
methylarginines may be elevated due to the combination
of increased elaboration and reduced elimination. More-
over, there is experimental and clinical evidence indicat-
ing a causal relationship between development of oxida-
tive stress and elevation of ADMA. For example, oxida-
tive stress enhances the activity of protein arginine
methyltransferase and compromises the activity of di-
methylarginine dimethylaminohydrolase. This subse-
quently provokes profound accumulation of ADMA. In
the presence of high ADMA levels, active dimeric iso-
forms of NOS may become uncoupled and a new catalyt-
ic function of NOS is established: generation of superox-
ide anion. In this way, ADMA is not just a marker but al-
so a mediator of oxidative stress (14).
Variable levels of ADMA and SDMA were recently
described in different clinical settings, with the highest
concentration of ADMA being found in septic patients.
Although a correlation between ADMA and organ failure
has been described, the data are still controversial (15-
17). Moreover, little attention has been paid to the role of
SDMA and adverse outcome in critically ill patients. We
aimed to investigate the trend of ADMA and SDMA in
high-risk patients with severe sepsis and septic shock,
and to elucidate the relationship between dimethy-
larginines, organ failure, sepsis status and ICU mortality.
PATIENTS AND METHODS
The study was approved by the hospital ethics com-
mittee and informed written consent was obtained from
each patient or a first-degree relative. Consecutive pa-
tients with severe sepsis or septic shock (18) were en-
rolled between December 2004 and March 2007 in 3
general adult Italian ICUs. 
Patients were treated according to the Surviving Sep-
sis Campaign (19). On the day of admission, artificial
nutrition (enteral, mixed or parenteral), intended to deliv-
er 25 kcal/kg/day as maximum level of nutritional sup-
port was started in all patients. Blood glucose level was
not allowed to exceed 180 mg/dL. 
Blood sampling was performed immediately after
enrolment (T0) and on the third (T3), sixth (T6) and
twelfth (T12) day. ADMA and SDMA were determined
in plasma by extraction and high performance liquid
chromatography (HPLC) assay as previously described
(20). Briefly, 0.1 mL plasma supplemented with L-ho-
moarginine as internal standard (50 µL; 1 nmol) was ap-
plied to a cation-exchange solid-phase extraction car-
tridge (Phenomenex STRATA SCX 100 mg/mL,
Chemtek Analitica, Bologna, Italy) previously activated
with methanol (1 mL) and trichloroacetic acid (TCA)
(2%, 2mL). After the column washings (TCA 2%, 150
mmol/L phosphate buffer pH 8.0, methanol), the amino
acids were eluted with 1 mL of 2% triethylamine solution
in methanol:water; 70:30; v:v). The eluate was dried un-
der nitrogen, redissolved in 0.1 mL bidistilled water, and
derivatized with ortho-phthaldialdehyde reagent (1:1; v:v,
1 min) before analysis. The HPLC device was equipped
with a fluorescent detector (λ 340 nm, λem 455 nm) and an
Ultrasphere ODS (250x4.6mm, 5 m) column. Baseline
separation of the methylated arginines was achieved with
a gradient between mobile phase A (sodium citrate buffer,
50 mmol/L, pH 6.2) and B (distilled water:acetonitrile:
methanol; 1:2:2; v:v:v). 
We collected the Simplified Acute Physiology Score
II (SAPS II) (21) at ICU admission, and, at any sampling
time, Sequential Organ Failure Assessment (SOFA)
score (22), sepsis status (18), standard blood parameters
(creatinine, bilirubin, platelets, white blood cells, mean
daily glucose concentration, pH) and ICU outcome. AD-
MA and SDMA levels were compared to normal values.
The average daily level of both amino acids during ICU
stay was compared between patients who developed sep-
tic shock and those who did not. For each time point, we
checked the relationship between ADMA/SDMA levels
and preexisting comorbidities, diagnosis, SAPS II at ad-
mission, and daily values of SOFA score, sepsis status
and blood parameters. Moreover, we compared at each
time point the daily values of dimethylarginines regis-
tered in deceased vs surviving patients. We checked also
which of these variables were associated with ICU mor-
tality.
Statistical analysis
All data are expressed as mean ± standard deviation
(SD). We used Anova with Scheffe’s correction and Stu-
dent’s t-test to assess differences between groups. Relation-
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ship was assessed by linear regression analysis. For each
time point we built a multivariate regression model with
variables selected by univariate analysis. 
We tested a general linear mixed model for repeated
measures based on every single patient for ICU mortali-
ty. The variables associated with ICU mortality assessed
by means of univariate logistic regression analysis were
included with the stepwise technique into a multivariate
logistic regression model. Odds ratios (OR) for each
variable were computed. The ability of the final model to
predict outcome was assessed by the area under the re-
ceiver operating characteristic (ROC) curve. Calibration
ability was measured with the Hosmer-Lemeshow good-
ness-of-fit test. 
We considered p < 0.05 to be statistically significant.
Statistical analysis was performed using the Stata statisti-
cal software, release 9.2 (Stata Corporation, College Sta-
tion, TX, USA). 
RESULTS
Twenty-nine consecutive patients were enrolled in
the study. The demographics of the study population are
given in Table I. Only T0 and T3 blood samples were
available for analysis in 2 patients; 8 patients had blood
samples until T6 and 19 patients had blood samples
available for the 4 time points. 
ADMA (0.98 ± 0.48 µmol/L) and SDMA (2.1 ± 1.05
µmol/L) levels at T0 were 2 and 5 times higher, respec-
tively, than those found in healthy volunteers (77 healthy
volunteers, 38 male, age 41 ± 16 years, creatinine value
0.76 ± 0.13 mg/100 mL) and did not decrease during
treatment (Tab. II). Sixteen patients who suffered septic
shock during ICU stay had a higher average value of dai-
ly ADMA (1.15 ± 0.51 µmol/L, n = 56 vs 0.91 ± 0.33
µmol/L, n = 48, p = 0.0084) and SDMA (2.71 ± 1.52
µmol/L, n = 56 vs 1.72 ± 0.89 µmol/L, n = 48, p =
0.0001) than patients with only severe sepsis. 
ADMA was significantly related to arterial pH (T0: b
= -1.85 R2 = 0.35 p = 0.028; T3: b = -4.51 R2 = 0.587 p =
0.003). SDMA was related at T0 (R2 = 0.295) to diabetes
mellitus (b = 1.104 p = 0.016), SAPS II (b = 0.32 p =
0.049), and arterial pH level (b = -4.3 p = 0.031). More-
over, SDMA was related at T3 (R2 = 0.715), T6 (R2 =
0.690) and T12 (R2 = 0.980) to daily SOFA score (T3: b
= 0.163 p = 0.006; T6: b = 0.2 p = 0.027) and creatinine
(T3: b = 0.403 p = 0.001; T6: b = 0.466 p = 0.009; T12: b
= 0.826 p = 0.007).
The SDMA concentration was significantly higher in
dead than alive patients at T3, T6 and T12 as represented
in Figure 1. Independent variables predicting ICU mor-
tality in the linear mixed model were SAPS II on admis-
sion (OR = 1.08 per point, p = 0.017), mean SOFA score
during ICU stay (OR = 1.39 per point, p < 0.0001) and
SDMA (OR = 2.25, p = 0.002). The area under the ROC
curve was 0.912. Calibration ability gave a p = 0.9625. 
TABLE I - DEMOGRAPHICS OF STUDY POPULATION 
Number of patients 29
Gender male/female 21/8
Age (mean ± SD) 62 ± 11
Admission day
Type: Medical / Surgical 23/6
Pneumonia 15 (57.69%)
Peritonitis 6 (22.22%)
Urinary infection 5 (19.23%)
Fournier’s syndrome 1 (3.44%)
Osteomyelitis 1 (3.44%)
Soft tissue infection 1 (3.44%)
SAPS II (points) 43.9 ± 12.0
Septic shock 14/29 (48.3%)
SOFA score (points) 9.3 ± 3.7
SOFA score (organ system ≥ 3 points)   
Respiratory failure 21/29 (72.4%)  
Coagulation failure 6/29 (20.7%)  
Hepatic failure 3/29 (10.3%)  
Cardiovascular failure 18/29 (62.1%)  
Neurological failure 1/29 (3.5%)  
Renal failure 5/29 (17.24%)  
Whole ICU stay   
Worst SOFA score 9.9 ± 3.2
Septic shock 16/29 (55.2%)
Length of stay (days) 16.3 ± 10.6
Mortality 7/29 (24.1%)
SAPS II, Simplified Acute Physiology Score II; SOFA, Sequential Organ Fai-
lure Assessment; ICU, intensive care unit
TABLE II - DIMETHYLARGININE LEVELS BY TIME POINTS 
Number ADMA SDMA
Healthy volunteers 77 0.46 ± 0.12 0.43 ± 0.99
(0.19-0.73) (0.19-0.66)
Patients
T0 29 0.99 ± 0.49 2.10 ± 1.06
(0.41-2.48) (0.81-4.09)
T3 29 1.06 ± 0.47 2.31 ± 1.20 
(0.52-2.43) (0.60-5.39)
T6 27 1.09 ± 0.49 2.26 ± 1.47
(0.54-2.73) (0.57-6.79)  
T12 19 1.03 ± 0.32 2.38 ± 1.84
(0.68-1.8) (0.75-8.16)  
Mean values of ADMA and SDMA in mol/L at each time point in study popu-




There are at least 2 interesting reasons for studying
methylarginines in critically ill patients. Methylarginines
could be a marker of protein breakdown like other
methylated amino acids (23) but of greater importance
because specifically deriving from nuclear proteins (2,
3). Moreover, ADMA and SDMA could have a metabol-
ic role that is closely related to the development of sys-
temic inflammatory reactions (8-10).
A population of highly stressed critically ill patients
is a prerequisite to testing these hypotheses. For this pur-
pose we chose to study patients with severe sepsis (18).
The patients selected for our study were really at high
risk (24): about 80% had pneumonia and peritonitis, and
more than 50% had septic shock. The severity of their
condition and their organ failures (more than 60% of pa-
tients were admitted with severe respiratory and cardio-
vascular dysfunction) resulted in a considerable mortali-
ty rate and a quite long ICU stay (Tab. I). 
In this setting, ADMA and SDMA plasma levels
were 2 and 5 times higher, respectively, than in healthy
volunteers on the day of admission and all along the ICU
stay. The ADMA levels in our study were similar to those
recently reported in the only study on septic patients (17)
but were higher than those reported in less critically ill
patients (15, 16). In fact, in addition to increased produc-
tion and reduced elimination (organ failure), oxidative
stress and cytokine release may cause reduction of di-
methylarginine dimethylaminohydrolase activity  in liv-
er, kidney and pancreas, further contributing to the in-
crease in ADMA levels (25, 26). Concerning SDMA, we
observed a greater accumulation compared with data re-
ported in the only study on critically ill patients where
SDMA was evaluated (15). Unfortunately, SDMA evalu-
ation is lacking in the study by O’Dwyer et al on patients
with septic shock (17). 
The main determinants of dimethylarginine concen-
trations at ICU admission were preexisting diabetes (SD-
MA and a trend for ADMA), as already observed (27),
blood acidosis (SDMA and ADMA), and severity of
acute organ failure (SDMA), previously described by
O’Dwyer only for ADMA. The impact of diabetes, sever-
ity of clinical conditions, and acidosis on dimethy-
larginines could be explained by an increased chronic
and acute body protein catabolism due to a stress state.
In the following ICU days, during a full-blown stress
reaction we found a close relationship between SDMA
(and not ADMA as reported in the literature by Nijveldt et
al [15] and O’Dwyer et al [17]) and the number and sever-
ity of organ failure. Moreover, SDMA concentration was
strongly and independently related to the presence of re-
nal failure. This is not surprising since urinary excretion
is the main eliminating process in humans (6, 7). 
In conclusion, ADMA but particularly SDMA seem
to be reliable markers of derangements of vital functions
in critical conditions. We registered overall ICU stay AD-
MA and SDMA concentrations that were 20% and 63%
higher, respectively, in patients who developed septic
shock during ICU stay in comparison to patients with se-
vere sepsis as the highest level of septic status. Moreover,
SDMA levels were higher in dead than in alive patients
during the entire ICU stay (Fig. 1). 
Dimethylarginines could play a role in organ damage
in sepsis. Overproduction of NO as part of the inflamma-
tory/immune response to infection is implicated in the
genesis of sepsis (28). In animal and human studies the
nonselective inhibitors of both constitutive and inducible
isoforms of NOS gave evidence that inhibition of the
constitutive NOS is unfavorable (13, 28-30). High di-
methylarginine concentrations, through a reduction of
arginine cell transport and/or a nonselective block of
constitutive NOS, may contribute to pathological
changes in the vascular wall, resulting in impaired organ
blood flow, endothelial damage, interstitial edema, and
immunological changes interfering with physiological
functions of NO. These features subsequently impair the
already compromised organs and place other organs at
risk of taking part in the cascade of failing organs. 
Interestingly, available studies in critically ill patients
show that ADMA is an independent predictive factor of
ICU mortality for the most severe patients (highest quar-
tile of statistical distribution - 15) or that an ADMA in-
crease between day 0 and day 2 and between day 7 and
the last day of ICU stay are significantly related to ICU
Fig. 1 - SDMA concentration in dead or alive patients during ICU
stay. Values in μmol/L are depicted as median, interquartile range
and upper and lower reference range. 
*p < 0.01. Pts., number of patients
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mortality (16). By contrast with literature data (15-17), in
our patients ADMA appeared a less potent indicator both
of organ failure and ICU survival, probably because of
the high variability. SDMA, on the other hand, is an inde-
pendent predictor of ICU mortality as well as robust clin-
ical parameters like SAPS II and mean SOFA score of
the whole ICU stay. The literature’s hypothesis that di-
methylarginines could play a specific role in the mi-
crovascular derangement associated with sepsis seems
therefore reasonable.
CONCLUSIONS
We found elevated levels of dimethylarginines in
high-risk critically ill patients with sepsis syndrome. Tak-
en together, our results strongly suggest that dimethy-
larginines are not only markers of body catabolism but
may have a high metabolic activity, tightly related to the
risk of adverse outcome of sepsis syndrome.
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